Pretreatment Determination of the Serum Urokinase Plasminogen Activator and its Soluble Receptor in Advanced Small-Cell Lung Cancer or Non-Small-Cell Lung Cancer

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Clinical and applied thrombosis/hemostasis

• Publication date

  2003-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1177/107602960300900309PMID 14507113
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The circulating urokinase plasminogen activator (uPA) and its soluble receptor (suPAR) are not up-regulated by the circulating P105 fraction of the HER-2/neu proto-oncogene: in vivo evidence from patients with advanced non-small cell lung cancer (NSCLC).

  2002cited by this paper
• Predicting the sites of metastases from lung cancer using molecular biologic markers.

  2001cited by this paper
• The urokinase-type plasminogen activator system in resected non-small-cell lung cancer. Rotterdam Oncology Thoracic Study Group.

  2000cited by this paper
• Overexpression level of stromelysin 3 is related to the lymph node involvement in non-small cell lung cancer.

  2000cited by this paper
• Relationship of urokinase and urokinase receptor in non-small cell lung cancer to proliferation, angiogenesis, metastasis and patient survival.

  1999cited by this paper
• Increased levels of urokinase receptor in plasma of head and neck squamous cell carcinoma patients.

  1999cited by this paper
• Posttranscriptional regulation of urokinase receptor gene expression in human lung carcinoma and mesothelioma cells in vitro

  1999cited by this paper
• [Urokinase plasminogen activator /U-PA/in blood of patients with lung cancer].

  1998cited by this paper
• Cancer cells overexpress mRNA of urokinase‐type plasminogen activator, its receptor and inhibitors in human non‐small‐cell lung cancer tissue: Analysis by Northern blotting and in situ hybridization

  1998cited by this paper
• Elevated plasma levels of urokinase plasminogen activator receptor in non-small cell lung cancer patients.

  1997cited by this paper
• Defective cell migration in an ovarian cancer cell line is associated with impaired urokinase‐induced tyrosine phosphorylation

  1997cited by this paper
• Evidence for preferential adhesion of ovarian epithelial carcinoma cells to type I collagen mediated by the alpha2beta1 integrin.

  1996cited by this paper
• Urokinase plasminogen activator in ovarian cancer.

  1996cited by this paper
• Evidence for preferential adhesion of ovarian epithelial carcinoma cells to type I collagen mediated by the αA2β1 integrin

  1996cited by this paper
• Up-regulation of urokinase-type plasminogen activator expression by the HER2/neu proto-oncogene.

  1995cited by this paper
• Co‐expression of urokinase, urokinase receptor and PAI‐1 is necessary for optimum invasiveness of cultured lung cancer cells

  1995cited by this paper
• Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue.

  1994cited by this paper
• c-erbB-2/neu overexpression enhances metastatic potential of human lung cancer cells by induction of metastasis-associated properties.

  1994cited by this paper
• Components of the Plasminogen-Plasmin System in Human Tumor Cell Lines

  1991cited by this paper
• The concentration of tissue plasminogen activator and urokinase in plasma and tissues of patients with ovarian and uterine tumors.

  1990cited by this paper
• Role of plasmin in the degradation of the stroma-derived fibrin in human ovarian carcinoma.

  1990cited by this paper
• [Relation between blood coagulability and prognosis in patients with ovarian cancer].

  1990cited by this paper

• Soluble Urokinase Plasminogen Activator Receptor Is Associated With Subclinical Myocardial Impairment by Speckle Tracking Echocardiography in Lung Cancer Patients

  2022cites this paper
• Soluble Urokinase Plasminogen Activator Receptor (suPAR) as a Biomarker of Systemic Chronic Inflammation

  2021cites this paper
• Immune-mediated entities of (primary) focal segmental glomerulosclerosis

  2021cites this paper
• Serum Levels of Soluble Urokinase Plasminogen Activator Receptor Predict Tumor Response and Outcome to Immune Checkpoint Inhibitor Therapy

  2021cites this paper
• Soluble urokinase plasminogen activator receptor (suPAR) as a prognostic marker of mortality in healthy, general and patient populations: protocol for a systematic review and meta-analysis

  2020cites this paper
• Prognostic effects of SuPAR and Neopterin Levels on Patients with Lung Cancer

  2020cites this paper
• Validation of suPAR turbidimetric assay on Cobas® (c502 and c702) and comparison to suPAR ELISA

  2020cites this paper
• Determination of urokinase-type plasminogen activator serum levels in healthy and oncologic cats.

  2020cites this paper
• uPAR-expressing melanoma exosomes promote angiogenesis by VE-Cadherin, EGFR and uPAR overexpression and rise of ERK1,2 signaling in endothelial cells

  2020cites this paper
• Multibiomarker analysis in patients with acute myocardial infarction

  2017cites this paper
• Serum levels of urokinase-type plasminogen activator in healthy dogs and oncologic canine patients

  2017cites this paper
• Inflammatory biomarkers and cancer: CRP and suPAR as markers of incident cancer in patients with serious nonspecific symptoms and signs of cancer

  2017cites this paper
• Podocyte directed therapy of nephrotic syndrome—can we bring the inside out?

  2016cites this paper
• Full-length soluble urokinase plasminogen activator receptor down-modulates nephrin expression in podocytes

  2015cites this paper
• Lung Cancer Biomarkers.

  2015cites this paper
• Involvement of Urokinase‐Type Plasminogen Activator System in Cancer: An Overview

  2014cites this paper
• Current Serum Lung Cancer Biomarkers

  2013cites this paper
• Serum suPAR in patients with FSGS: trash or treasure?

  2013cites this paper
• Current Serum Lung Cancer Biomarkers

  2013cites this paper
• Functional protease profiling for diagnosis of malignant disease

  2012cites this paper
• Synthesis and biological characterization of protease-activated prodrugs of doxazolidine.

  2012cites this paper
• Clinical applications of the urokinase receptor (uPAR) for cancer patients.

  2011cites this paper
• Urokinase-Rezeptor (uPAR) und Zellkontakte : Mechanismen uPAR-abhängiger Zelladhäsion, Zellmigration und Signaltransduktion

  2011cites this paper
• Prognostic significance of urokinase plasminogen activator receptor and its cleaved forms in blood from patients with non‐small cell lung cancer

  2009cites this paper
• The urokinase plasminogen activator system: a target for anti-cancer therapy.

  2009cites this paper
• Tumour cell expression of C4.4A, a structural homologue of the urokinase receptor, correlates with poor prognosis in non-small cell lung cancer.

  2007cites this paper
• Urokinase receptor variants in tissue and body fluids.

  2007cites this paper
• Prognostic impact of liberated domain I of the urokinase plasminogen activator receptor in squamous cell lung cancer tissue.

  2005cites this paper
• An Approach to Studying Lung Cancer-related Proteins in Human Blood*S

  2005cites this paper